CoChat
Sign Up
Cited by 720

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Clonal evolution of glioblastoma under therapy

Wang, Jiguang, Cazzato, Emanuela, Ladewig, Erik, Frattini, Veronique, Rosenbloom, Daniel I S, Zairis, Sakellarios, Abate, Francesco, Liu, Zhaoqi, Elliott, Oliver, Shin, Yong-Jae, Lee, Jin-Ku, Lee, In-Hee, Park, Woong-Yang, Eoli, Marica, Blumberg, Andrew J, Lasorella, Anna, Nam, Do-Hyun, Finocchiaro, Gaetano, Iavarone, Antonio, Rabadan, Raul·2016·Nature Genetics
DOI 10.1038/ng.3590PMC PMC5627776
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ng.3590

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 50

  1. Ricard, D. et al. Primary brain tumours in adults. Lancet 379, 1984–1996 (2012). · DOI
  2. Frattini, V. et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat. Genet. 45, 1141–1149 (2013). · DOI · Paper page
  3. Mazor, T. et al. DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28, 307–317 (2015). · DOI
  4. Kim, J. et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28, 318–328 (2015). · DOI
  5. Kim, H. et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 25, 316–327 (2015). · DOI · Paper page
  6. Nordling, C.O. A new theory on cancer-inducing mechanism. Br. J. Cancer 7, 68–72 (1953). · DOI
  7. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8, 1–12 (1954). · DOI · Paper page
  8. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110, 4009–4014 (2013). · DOI · Paper page
  9. Gill, B.J. et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc. Natl. Acad. Sci. USA 111, 12550–12555 (2014). · DOI
  10. Suzuki, H. et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat. Genet. 47, 458–468 (2015). · DOI · Paper page
  11. Trifonov, V., Pasqualucci, L., Tiacci, E., Falini, B. & Rabadan, R. SAVI: a statistical algorithm for variant frequency identification. BMC Syst. Biol. 7 (suppl. 2), S2 (2013). · DOI
  12. Melamed, R.D., Wang, J., Iavarone, A. & Rabadan, R. An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. J. Mol. Cell Biol. 7, 203–213 (2015). · DOI
  13. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22, 398–406 (2012). · DOI
  14. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013). · DOI · Paper page
  15. Stieglitz, E. et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat. Genet. 47, 1326–1333 (2015). · DOI
  16. Hunter, C. et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 66, 3987–3991 (2006). · DOI
  17. Yip, S. et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622–4629 (2009). · DOI
  18. Cahill, D.P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038–2045 (2007). · DOI
  19. Miyazono, K., Olofsson, A., Colosetti, P. & Heldin, C.H. A role of the latent TGF-β1–binding protein in the assembly and secretion of TGF-β1. EMBO J. 10, 1091–1101 (1991). · DOI
  20. Sterner-Kock, A. et al. Disruption of the gene encoding the latent transforming growth factor-β binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev. 16, 2264–2273 (2002). · DOI
  21. Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011). · DOI
  22. Trifonov, V., Pasqualucci, L., Dalla Favera, R. & Rabadan, R. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC Syst. Biol. 7, 25 (2013). · DOI
  23. Singh, D. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231–1235 (2012). · DOI
  24. Di Stefano, A.L. et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin. Cancer Res. 21, 3307–3317 (2015). · DOI
  25. Hegi, M.E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005). · DOI · Paper page
  26. Schneider, T.D. & Stephens, R.M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097–6100 (1990). · DOI
  27. Sakellarios Zairis, H.K., Blumberg, A. & Rabadan, R. Moduli spaces of phylogenetic trees describing tumor evolutionary patterns. Lect. Notes Computer Sci. 8609, 528–839 (2014). · DOI
  28. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988). · DOI
  29. Yates, L.R. & Campbell, P.J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795–806 (2012). · DOI
  30. Wang, J. et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. eLife 3, e02869 (2014). · DOI
  31. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012). · DOI
  32. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014). · DOI
  33. Kuan, C.T., Wikstrand, C.J. & Bigner, D.D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83–96 (2001). · DOI
  34. Torres-García, W. et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224–2226 (2014). · DOI
  35. Anido, J. et al. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655–668 (2010). · DOI
  36. Han, J., Alvarez-Breckenridge, C.A., Wang, Q.E. & Yu, J. TGF-β signaling and its targeting for glioma treatment. Am. J. Cancer Res. 5, 945–955 (2015).
  37. Joseph, J.V., Balasubramaniyan, V., Walenkamp, A. & Kruyt, F.A. TGF-β as a therapeutic target in high grade gliomas—promises and challenges. Biochem. Pharmacol. 85, 478–485 (2013). · DOI
  38. Kaminska, B., Kocyk, M. & Kijewska, M. TGF β signaling and its role in glioma pathogenesis. Adv. Exp. Med. Biol. 986, 171–187 (2013). · DOI
  39. Massagué, J. TGFβ in cancer. Cell 134, 215–230 (2008). · DOI · Paper page
  40. Fakhrai, H. et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93, 2909–2914 (1996). · DOI
  41. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002). · DOI · Paper page
  42. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013). · DOI · Paper page
  43. Khalili, J.S., Hanson, R.W. & Szallasi, Z. In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. OncoImmunology 1, 1281–1289 (2012). · DOI
  44. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004). · DOI
  45. Magi, A. et al. EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol. 14, R120 (2013). · DOI
  46. Iyer, M.K., Chinnaiyan, A.M. & Maher, C.A. ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903–2904 (2011). · DOI
  47. Abate, F. et al. Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. BMC Syst. Biol. 8, 97 (2014). · DOI
  48. Niola, F. et al. Mesenchymal high-grade glioma is maintained by the ID–RAP1 axis. J. Clin. Invest. 123, 405–417 (2013). · DOI
  49. Carro, M.S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318–325 (2010). · DOI
  50. Zhao, X. et al. The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643–653 (2008). · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D. I. S., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.-J., Lee, J.-K., Lee, I.-H., Park, W.-Y., Eoli, M., Blumberg, A. J., Lasorella, A., Nam, D.-H., Finocchiaro, G., Iavarone, A., & Rabadan, R.
ORCID
Rosenbloom, Daniel I S
Venue
Nature Genetics
Publisher
Springer Science and Business Media LLC
Published
2016-06-06
Volume
48
Issue
7
Pages
768-776
ISSN
  • 1061-4036
  • 1546-1718
DOI
10.1038/ng.3590
PMC
PMC5627776
Cited by
720
References
11
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review